SentinelOne (S) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bio-Techne faces significant macro and policy headwinds, including reduced academic research funding, China risks, and U.S.

Shares of EverQuote (EVER) have gained 6.4% over the past four weeks to close the last trading session at $24.61, but there ...

Circle’s IPO highlights crypto’s mainstream shift, with USDC driving revenue and new fintech services expanding its reach.

But the decision today (6 June) could reverse this ban, as long as the crypto ETN is traded on an FCA-approved investment ...

What began as Elon Musk's embrace of right-wing populism has become a defining — and potentially harmful — chapter in his ...

Companies must be held accountable for their depredations before the next scramble for the continent under the guise of a ...

The U.S. stock rebound has driven key indexes to the cusp of record levels, with fresh economic data and trade and fiscal ...

By the closing bell, the blue-chip Dow Jones Industrial Average was up 1.1% at 42,762, the broad-based S&P 500 had added 1.0% ...

Wall Street this week cautiously rallied, betting President Donald Trump might take a softer tone on his trade war. Investors ...